| Objective To systematically evaluate the efficacy and safety of Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia, and to provide references for intervention protocols for antipsychotic-induced hyperprolactinemia patients. Methods English databases (PubMed, Cochrane Library, PsycINFO, and EMBASE) and Chinese databases (CNKI and Wanfang) were systematically searched, with a search time frame of the period from database creation to September 16, 2022. Randomized controlled studies (RCTs) on adjunctive Tianmeng Oral Liquid in the treatment of hyperprolactinemia caused by antipsychotics in female patients with schizophrenia. Three investigators independently screened the literature and extracted data according to PICOS principles and evaluated the quality of each including RCT methodology, and the Meta-analysis was performed by using Revman 5.3. Results A total of 3 articles including 256 female schizophrenic patients with hyperprolactinemia were included. Meta-analysis results show that at the treatment endpoint, the improvement of hyperprolactinemia symptoms reported a significant superiority of the intervention group than the control group (RR=1.73, 95% CI: 1.07~2.79, P?0.05). Similarly, the significant superiority of the intervention group than the control group were also found in reducing serum prolactin levels (WMD=-55.17, 95% CI: -68.16~-42.18, P<0.01) and lower total scores of Positive and Negative Syndrome Scale (PANSS) (WMD=-7.36, 95% CI: -8.94~-5.77, P<0.01). Conclusion Tianmeng Oral Liquid may help improve clinical efficacy and reduce serum prolactin levels in female schizophrenia patients with hyperprolactinemia. It may improve psychiatric symptoms in female patients with schizophrenia. |